Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2398 | PLACEBO GROUP Wiki | 0.71 |
| drug2853 | Relaxation Therapy Wiki | 0.71 |
| drug388 | BCG GROUP Wiki | 0.71 |
Navigate: Correlations HPO
There are 2 clinical trials
Anxiety is among the most prevalent, costly and disabling illnesses and tends emerge early in childhood. Cognitive behavioral therapy (CBT) is the first-line treatment for early life anxiety, but as many as 40% of young patients who receive CBT fail to get better. The proposed study will examine brain changes marking positive response to CBT for anxiety and how these changes may differ in children compared adolescents. By helping us to understand how CBT works, this study will pave the way for new treatments to stop anxiety early.
Description: Pre- to post-CBT changes in functional, connectivity and structural MRI measures of brain networks relevant for anxiety. Brain regions include the amygdala, anterior insula, dorsal anterior cingulate cortex (dACC) and ventrolateral prefrontal cortex (vlPFC). Functional activation and connectivity of these brain regions are assessed using simple computer tasks performed during MRI scanning. Tasks engage threat reactivity, self-regulatory control and the interaction of these processes. Structural connections between regions will be measured using a MRI technique that measures water diffusion in the brain.
Measure: Brain function/structure as assessed by Magnetic Resonance Imaging scans Time: Baseline and 12-weeksDescription: The Pediatric Anxiety Rating Scale (PARS) is a clinician-administered assessment to rate the severity of anxiety symptoms associated with common DSM-V anxiety disorders (social phobia, separation anxiety disorder, and generalized anxiety disorder) in children. The investigators are looking for decreases in anxiety severity ratings from pre- to post-treatment.
Measure: Pediatric Anxiety Rating Scale Time: weeks 0, 3, 6, 9, 12Mobile applications are more and more considered when implementing programs for treating mental disorders. The study aims to reduce avoidance and fear of spiders in spider-fearful individuals by combining exposure principles with gamification elements (e.g. narrative background, level progression, points, feedback). We investigate the efficacy of the gamified app in a remote online-therapy context.
Description: Scores range from 0 ("participant refuses to enter the room with spider") to 12 ("participant holds the spider at least for 20 sec").
Measure: Change in avoidance behavior (Behavioral Approach Task; BAT) Time: Baseline; (after one-session exposure if applied); Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Description: The scale ranges from 0-31. High scores reflect high subjective levels and low scores low subjective levels of spider fear.
Measure: Change in spider fear (Spider Phobia Questionnaire; SPQ) Time: Baseline; Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Description: The scale ranges from 0-108. High scores reflect high subjective levels and low scores low subjective levels of spider fear.
Measure: Change in spider fear: Spider-Anxiety Questionnaire (FAS) Time: Baseline; Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Description: Seven-point rating scale scoring from 0 to 6: high scores reflect high levels and low scores low levels of experienced disgust; participants play twice a day (between 8 - 11 am and 4 - 7 pm); ratings are part of the app
Measure: Change in disgust before and after playing the app Time: Before starting and immediately after completing the gameDescription: Seven-point rating scale scoring from 0 to 6: high scores reflect high levels and low scores low levels of experienced arousal; participants play twice a day (between 8 - 11 am and 4 - 7 pm); ratings are part of the app
Measure: Change in arousal before and after playing the app Time: Before starting and immediately after completing the gameDescription: Seven-point rating scale scoring from 0 to 6: high scores reflect high levels and low scores low levels of experienced anxiety; participants play twice a day (between 8 - 11 am and 4 - 7 pm); ratings are part of the app
Measure: Change in anxiety before and after playing the app Time: Before starting and immediately after completing the gameDescription: Measures severity of depression; The scale ranges from 0-63: 0-13 minimal depressive symptoms; 14-19 mild symptoms; 20-28 moderate symptoms; 29-63 severe symptoms.
Measure: Beck Depression Inventory II (BDI-II) Time: Baseline, Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Description: Measures clinically relevant psychological symptoms.
Measure: Brief Symptom Inventory (BSI) Time: Baseline, Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Description: Standardised satisfaction measurement
Measure: German version of the Client Satisfaction Questionnaire (CSQ-8) Time: (after one-session exposure if applied), Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Description: Questionnaire assessing the quality of new user-oriented health applications
Measure: Mobile Application Rating Scale (MARS) Time: Post-treatment (1-week after baseline)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports